Quince Therapeutics, Inc. (QNCX)

Market Cap	17.93M -60.5%
Revenue (ttm)	n/a
Net Income	-33.04M
EPS	-6.86
Shares Out	16.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,229,399
Open	1.040
Previous Close	1.070
Day's Range	1.040 - 1.130
52-Week Range	0.790 - 45.499
Beta	1.45
Analysts	Hold
Price Target	n/a
Earnings Date	May 11, 2026

About QNCX

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a dr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 38
• Stock Exchange: NASDAQ
• Ticker Symbol: QNCX
• Website: https://quincetx.com